(Q45070061)

9 December 2017

Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. (English)

1 reference

9 December 2017

0 references

1 reference

1 reference

8

1 reference

9 December 2017

7

Mario Rizzetto

1 reference

9 December 2017

Vito Di Marco

1

1 reference

9 December 2017

Alfredo Marzano

2

1 reference

9 December 2017

Pietro Lampertico

3

1 reference

9 December 2017

Pietro Andreone

4

1 reference

9 December 2017

Teresa Santantonio

5

1 reference

9 December 2017

Piero Luigi Almasio

6

1 reference

9 December 2017

Italian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy

9

1 reference

9 December 2017

language of work or name

English

0 references

publication date

1 October 2004

1 reference

9 December 2017

1 reference

9 December 2017

40

1 reference

9 December 2017

4

1 reference

9 December 2017

883-891

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

9 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Management of hepatitis B: 2000--summary of a workshop

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Epidemiology of precore mutants of hepatitis B in the United Kingdom

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Comparison of anti-HBe-positive and HBe-antigen-positive chronic hepatitis B in France. French Multicentre Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen-negative chronic hepatitis B in Korea

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. The Investigators of the European Concerted Action on Viral Hepatitis (EUROHEP)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

The long-term course of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

A United States compassionate use study of lamivudine treatment in nontransplantation candidates with decompensated hepatitis B virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Clinical impact of lamivudine resistance in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Molecular diagnosis of viral hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Re-treatment of patients with anti-HBe-positive chronic hepatitis B who relapsed after an initial course of lamivudine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840400418

7 January 2021

Identifiers

DOI

10.1002/HEP.1840400418

1 reference

9 December 2017

1 reference